Recce Pharmaceuticals secures Chinese patent acceptance for its flagship anti-infective compounds, expanding its global IP footprint into the world’s second-largest pharmaceutical market.
( Image: ACB News)
█ ACB News Cathy
SYDNEY, 27 May 2025 – Recce Pharmaceuticals Ltd (ASX: RCE), an Australian biotech developing next-generation synthetic anti-infectives, has received official notification from the China National Intellectual Property Administration (CNIPA) confirming the acceptance of its core Patent Family 4, valid until 2041.
The newly accepted patent covers RECCE® 327 and RECCE® 529, including their manufacturing processes, therapeutic applications for bacterial and viral infections, and multiple delivery formats (oral, injection, transdermal, aerosol, etc.).
This is Recce’s fifth Patent Family 4 grant, following approvals in Australia, Canada, Israel, and Japan. Additional international applications under the Patent Cooperation Treaty (PCT) are under review.
CEO James Graham welcomed the decision, stating it marks a significant expansion of Recce’s global IP portfolio into China, the world’s second-largest pharmaceutical market, where the antibiotic sector alone is valued at US$4.09 billion and forecast to grow at a 5.7% CAGR through 2030.
Recce’s pipeline includes:
● R327: IV/topical therapy for drug-resistant bacterial infections
● R435: Oral antibacterial
● R529: Antiviral therapy
All three compounds have been recognised by the WHO and the FDA, with R327 receiving QIDP status, Fast Track designation, and 10-year post-approval market exclusivity.
Recce owns and operates its own automated manufacturing facility in Australia, supporting current clinical trials and future commercial supply.
This patent marks a key step in Recce’s global commercialisation strategy and its efforts to combat the global threat of antimicrobial resistance.
Copyright Notice:
ACB News reserves full copyright over all articles explicitly marked as "original" content.
No media outlet, corporate website, platform, or app within Australia may reproduce, excerpt, adapt, or republish such content in any form without prior written authorization from ACB News.
Any unauthorized use or reproduction—including via third-party platforms—will be considered an infringement. ACB News reserves the right to pursue legal action against any such violations.
